G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution
Guilin Tang,Liping Zhang,Bin Fu,Jianhua Hu,Xinyan Lu,Shimin Hu,Ankita Patel,Maitrayee Goswami,Joseph D. Khoury,Guillermo Garcia-Manero,L. Jeffrey Medeiros,Sa A. Wang +11 more
TL;DR: The study results strongly advocate for the incorporation of cytogenetic information in the risk model for CMML, with marked differences in OS within the proposed high risk group.
Journal ArticleDOI
Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)
Naval Daver,Sreyashi Basu,Guillermo Garcia-Manero,Jorge E. Cortes,Farhad Ravandi,Elias Jabbour,Stephany Hendrickson,Sherry Pierce,Jing Ning,Marina Konopleva,Michael Andreeff,Steven M. Kornblau,Naveen Pemmaraju,Carlos E. Bueso-Ramos,Jorge Blando,Juliana E. Hidalgo Lopez,James P. Allison,Hagop M. Kantarjian,Padmanee Sharma +18 more
TL;DR: 51 pts with a median age of 69 years, secondary AML, poor risk cytogenetics, and median number of prior regimens 2 (range, 1-7) have been enrolled and 35 pts are evaluable for response: 6 achieved complete remission (CR)/ complete remission with insufficient recovery of counts (CRi) and 5 had hematologic improvement (HI).
Journal ArticleDOI
Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Uma Borate,Jordi Esteve,Kimmo Porkka,Steve Knapper,Norbert Vey,Sebastian Scholl,Guillermo Garcia-Manero,Martin Wermke,Jeroen Janssen,Elie Traer,Chong Chyn Chua,Rupa Narayan,Natalia Tovar,Mika Kontro,Oliver G. Ottmann,Haiying Sun,Tyler Longmire,Sebastian Szpakowski,Serena Liao,Anuradha Patel,Mikael L. Rinne,Andrew M. Brunner,Andrew H. Wei +22 more
TL;DR: The primary objectives were to characterize the safety and tolerability of MBG453 in combination with decitabine and to identify recommended doses for future studies, and to assess preliminary efficacy and pharmacokinetics of the combination.
Journal ArticleDOI
A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS)
Guillermo Garcia-Manero,Naval Daver,Guillermo Montalban-Bravo,Elias Jabbour,Courtney D. DiNardo,Steven M. Kornblau,Prithviraj Bose,Yesid Alvarado,Maro Ohanian,Gautam Borthakur,Jorge E. Cortes,Kiran Naqvi,Naveen Pemmaraju,Xuelin Huang,Graciela M. Nogueras-Gonzalez,Carlos E. Bueso-Ramos,Yvonne Gasior,Virginia Bayer,Sherry Pierce,Hui Yang,Simona Colla,Hagop M. Kantarjian +21 more
TL;DR: It is hypothesized that use of these drugs after HMA failure or in combination with azacitidine (AZA) in the frontline setting may improve treatment outcomes of pts with MDS.
Journal ArticleDOI
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
Andrés E. Quesada,Mark J. Routbort,Courtney D. DiNardo,Carlos E. Bueso-Ramos,Rashmi Kanagal-Shamanna,Joseph D. Khoury,Beenu Thakral,Zhuang Zuo,C. Cameron Yin,Sanam Loghavi,Chi Young Ok,Sa A. Wang,Zhenya Tang,Sarah A. Bannon,Christopher B. Benton,Guillermo Garcia-Manero,Hagop M. Kantarjian,Rajyalakshmi Luthra,L. Jeffrey Medeiros,Keyur P. Patel +19 more
TL;DR: The recognition of myeloid neoplasms with DDX41 mutation as unique, need for germline confirmation, and further assessment of family members are supported.